



351 Phoenixville Pike, Malvern, PA
Phone: (610) 296-8660 □ Fax: (610) 296-8661
www.neotropix.com

FOR IMMEDIATE RELEASE

***Neotropix Announces Progress in Research Program,
Other Corporate Developments***

***Company to Host Open House on September 28 to Recognize Achievements and
Opening of New Research Facility***

Malvern, Pa, September 21, 2005 – Neotropix™, Inc., a rapidly growing biotechnology company dedicated to the development of virus-based therapies for the treatment of cancer and other diseases, today announced several significant corporate developments. On September 28, the company will recognize its achievements by hosting an Open House in its new cutting-edge facility. The ribbon-cutting ceremony will be held for invited guests and members of the media.

In the past year, Neotropix has experienced a number of significant events including:

- Completing research and development necessary to file an Investigational New Drug application for Neotropix's cancer drug candidate with the FDA, setting the company on course for Phase I clinical trial early in 2006.
- Securing a second tranche of funding of \$3.8 million from VIMAC Milestone Medica Fund, Quaker BioVentures, The Aurora Funds, and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania.
- Significantly increasing personnel in key positions, most of whom are focused on research and development.
- Selecting two new members for the Board of Directors: Chris Kroeger, M.D. of Aurora Funds and Dennis L. Panicali, Ph.D. of Therion Biologics Corporation.
- Adding Vincent R. Racaniello, Ph.D, a world renowned microbiologist and virologist at Columbia University, to the Neotropix Scientific Advisory Board.
- Moving to its new facilities at 351 Phoenixville Pike in Malvern, Pa. The new facility is designed to help advance the company's capabilities in research and development.
- Finally, Neotropix was recently selected as a finalist for the prestigious PricewaterhouseCoopers Enterprise Award of Life Sciences Startup Company of the Year.

This summer, Neotropix moved to a new 7,500-square-foot corporate and lab headquarters. The new facility includes the latest top-of-the-line lab equipment to help Neotropix significantly increase its research and development initiatives. The facility will enable Neotropix to reach its research and development milestones.

“Our Open House will recognize the accomplishments of our employees and supporters who have helped us establish a strong foundation,” stated Dr. Paul Hallenbeck, president and founder of Neotropix. “Neotropix is gaining recognition as a key player in the region's emerging biotech sector.”

Special guests at the Open House will include: Dennis Yablonsky, Pennsylvania's Secretary of Community and Economic Development; Gail Kronig, Governor's Action Team, and Robert Flick, PA State Representative of the 167th Legislative District.

###

About Neotropix

Based in Malvern, Pennsylvania, Neotropix™, Inc. is a rapidly growing biotechnology company dedicated to the development of virus-based therapies for the treatment of cancer and other diseases. Neotropix is conducting research on Seneca Valley Virus, a novel systemically deliverable oncolytic virus for the treatment of small cell lung cancer and other neuroendocrine cancers. The company has licensing agreements with Crucell and Novartis as research partners. Neotropix recently moved to new corporate and lab headquarters and is on target to begin first clinical trials for its cancer therapy early in 2006. Neotropix was founded by Dr. Paul Hallenbeck, a pioneer in the field of oncolytic viruses.

=====

For more information, please contact:

Janice Ingram

Event Contact

(610) 296-8660

JIngram@neotropix.com

Zoey Farooq

Press Contact

(617) 523-4141

zoey@morrisseyco.com